Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.78 |
| ▸ | GRM5 | P41594 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | FADS1 | O60427 | 2/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353976 | 0.86 | HDAC8 (0.77) | HDAC8MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL24118881 | 0.82 | STAT3 (0.75) | HDAC8GRM5MEN1KMT2ARAB9A | |
| SCHEMBL1352779 | 0.82 | HDAC8 (0.61) | HDAC8MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL1353005 | 0.82 | RXFP1 (0.64) | HDAC8MAPT | |
| SCHEMBL1351867 | 0.82 | HDAC8 (0.57) | HDAC8MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL24118801 | 0.82 | GRM5 (0.83) | HDAC8GRM5MEN1KMT2ARAB9A | |
| SCHEMBL1353390 | 0.81 | HDAC8 (0.62) | HDAC8MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL1353484 | 0.81 | NPC1 (0.71) | HDAC8MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL1353382 | 0.81 | KCNMA1 (0.58) | HDAC8MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL1353434 | 0.80 | HDAC8 (0.55) | HDAC8MEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-1698618-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1698618-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123493-A1 | Benzamide derivative | BDKRB1, BDKRB2, NR1H2 | HDAC8 305/4885GRM5 590/4885MEN1 3744/4885 |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | NR0B2, NR1H2, CNR2 | HDAC8 407/4885GRM5 562/4885MEN1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.